DC联合CIK细胞治疗对中晚期肝癌患者免疫功能及生活质量的影响  

作　　者：谭斌[1] 朱丹[1] 张长法[1] 潘雪飞[1] 

机构地区：[1]中国人民解放军第454医院肝病科,江苏210002

出　　处：《当代医学》2015年第26期64-65,共2页Contemporary Medicine

摘　　要：目的分析DC联合CIK细胞治疗对中晚期肝癌患者免疫功能及生活质量的影响。方法回顾性分析50例中晚期肝癌患者的临床资料,并采用流式细胞仪检测患者治疗前后免疫功能变化和生活质量情况。结果 50例患者治疗后,T辅助细胞、总T细胞、细胞毒T细胞、Th/Ts比值、调节T细胞、自然杀伤细胞以及NK-T细胞均比治疗前显著提高,治疗前后比较差异有统计学意义(P<0.05);治疗前卡氏评分平均为(75.4±10.2)分,而治疗后平均评分为(84.5±11.34)分,2组比较差异有统计学意义(P<0.05),无严重不良反应。结论 DC联合CIK细胞治疗中晚期肝癌患者,不仅能够有效提高患者免疫功能,改善患者生活质量,而且治疗安全性及可行性高,值得临床推广使用。Objective Analysis of DC combined with CIK cells for the effects on immune function in patients with liver cancer in advanced stage and quality of life.Methods Retrospective analysis Clinical data of 50 patients with advanced hepatocellular carcinoma and the use of lfow cytometry to detect the changes of immune function and quality of life before and after treatment.Results This group of 50 patients after treatment, T helper cells, total T cells, cytotoxic T cell, Th/Ts ratio, regulatory T cells, natural killer cells and NK-T cells were all improved than before treatment, after treatment, the difference has statistical signiifcance; Karnofsky performance status for an average of （75.4±10.2） points, and after treatment themean score of （84.5±11.34）, between the two groups difference is statistically signiifcant （P〈0.05）, no serious adverse reaction.Conclusion In patients with advanced hepatocellular carcinoma DC cells combined with CIK treatment, not only can improve the immune function of patients, improve the quality of life of patients, but also the treatment of safety and high feasibility, is worthy of clinical use.

关 键 词：中晚期肝癌 CIK细胞治疗 免疫功能 生活质量 

分 类 号：R735.7[医药卫生—肿瘤]